Combining Strength Training and Cardio Reduces Type 2 Diabetes Risk, Study Shows A study published in the Journal of the American Medical Association (JAMA) found that adults who engaged in …
Tag:
weight loss
-
-
Hyperemesis gravidarum (HG)—a severe form of pregnancy-related nausea and vomiting—is linked to a significantly higher risk of adverse maternal and fetal outcomes, including preterm birth and gestational hypertension. While standard …
-
Eli Lilly Announces Price Cut for Mounjaro Amid Cost-Effectiveness Debate Eli Lilly & Co. announced a significant price reduction for its diabetes drug Mounjaro in April 2024, according to a …
-
Ozempic and Cambrian Biotech’s Latest Developments: What You Need to Know Cambrian Biotech, a New York-based biotech startup, announced on Friday a significant advancement in its research into GLP-1 agonists, …
-
Understanding GLP-1 Receptor Agonists: Clinical Uses and Current Landscape Glucagon-like peptide-1 (GLP-1) receptor agonists, including medications like semaglutide and tirzepatide, have transformed the treatment landscape for type 2 diabetes and …
-
Understanding Weight Loss Variability with GLP-1 Receptor Agonists Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, produce significant weight loss in many patients, yet clinical outcomes vary widely …
-
GLP-1 Medications and Breast Cancer Risk: Examining Recent Findings A recent observational study suggests a potential link between the use of glucagon-like peptide-1 (GLP-1) receptor agonists and a reduced incidence …
-
The Physiological Impact of 36-Hour Fasting: Metabolic and Neurological Markers Recent clinical research indicates that prolonged fasting, specifically cycles lasting 36 hours, can induce significant shifts in metabolic processes and …
-
GLP-1 Medications Revolutionize Obesity Treatment, Study Shows GLP-1 receptor agonists, including semaglutide-based drugs like Ozempic and Wegovy, have significantly improved weight management outcomes, according to a 2023 meta-analysis published in …
-
AstraZeneca’s Oral GLP-1 Drug Shows Promise in Phase 2 Trials for Obesity and Diabetes AstraZeneca’s investigational oral GLP-1 drug, elecoglipron, has demonstrated significant potential in phase 2 trials for both …